Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer.
Anthracyclines are amongst the most active drugs in the treatment of breast cancer. Stealth liposomal doxorubicin (Caelyx, Doxil, Alza Pharmaceuticals Inc.) is a promising new agent under investigation for the treatment of breast cancer and other solid tumours. The liposomal encapsulation alters drug pharmacokinetics and leads to a marked change in toxicity profile compared to non-liposomal doxorubicin. The results of recently completed and ongoing clinical trials in breast cancer are reviewed.
Ranson
M R
MR
Department of Medical Oncology, Cancer Research Campaign, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M204BX, UK. malcolm.ransom@man.ac.uk
Cheeseman
S
S
White
S
S
Margison
J
J
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004317:Doxorubicin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008081:Liposomes
D000970:Antineoplastic Agents; D008081:Liposomes; D004317:Doxorubicin